Drug Profile
Research programme: multiple sclerosis therapies - Alberta/Novartis
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Alberta Innovates - Health Solutions; Novartis Pharmaceuticals Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Multiple-sclerosis in Canada
- 27 Nov 2013 Early research in Multiple sclerosis in Canada (unspecified route)